NCT06857292 Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 97 participants in total. It began in 2024-12-01 with a primary completion date of 2025-12.

Brief Summary

This study is a multicenter, single-arm, prospective study. The study population includes children with cancer who require high-intensity chemotherapy. The study aims to evaluate the safety and effectiveness of Telpegfilgrastim in preventing neutropenia in children with cancer (neuroblastoma, sarcoma, lymphoma, etc.) undergoing chemotherapy, while also studying the pharmacokinetic characteristics of Telpegfilgrastim in children with cancer.

Eligibility Criteria

Inclusion Criteria: * Patients with 14≤ age \< 18 years; * Newly diagnosed patients with non-myeloid malignancies who are confirmed by histopathology or cytology to require intensive chemotherapy (first course of chemotherapy or second course of chemotherapy); * Primary prevention (G-CSF 24 to 72 hours after the first use of chemotherapy agents with myelosuppression to prevent the occurrence of febrile neutropenia (FN)) or secondary prevention (if FN or dose-restricted neutropenia occurred in a patient during a previous chemotherapy cycle) is required. Prophylactic use of G-CSF can be considered for the next chemotherapy cycle. Febrile neutropenia (FN) : Oral temperature \>38.3 ° C (axillary temperature \>38.1 ° C) or oral temperature \>38.0 ° C (axillary temperature \>37.8 ° C) with ANC\<0.5×10\^9/L for 2 consecutive measurements within 2 hours, or ANC is expected to decrease to \<0.5×10\^9/L within 48 hours. * KPS score ≥50 or Lansky (LPS) score ≥50; * Normal hematopoietic function of bone marrow (ANC≥1.5×10\^9/L, PLT≥80×10\^9 /L, Hb≥75g/L, WBC≥3.0×10\^9/L, and not exceeding the upper limit of normal value); * Life expectancy of at least 6 months; ⑦ Obtain written informed consent. Exclusion Criteria: * Received any rhG-CSF within 3 weeks prior to study participation; * Received any antibody coupling drug (ADC) drugs with potential blood toxicity within 3 weeks before participating in the study; * Recipients of hematopoietic stem cell transplantation or organ transplantation; * Clinical trials of other drugs were being conducted within 2 months before enrollment; * There is no control of infection, body temperature ≥38℃; ⑥ Liver function test: total bilirubin (TBIL) alanine aminotransferase (ALT.) and aspartate aminotransferase (AST.) were more than 2.5 times the upper limit of normal value; ⑦ Renal function test: serum creatinine (Cr.) \> 1.5 times the upper limit of normal value; ⑧Other conditions considered by the researchers to be contraindications for this study.

Contact & Investigator

Frequently Asked Questions

Related Trials